Ticlopidine
Clopidogrel
Prasugrel

Thienopyridines are a class of selective, irreversible[1] ADP receptor/P2Y12 inhibitors used for their anti-platelet activity. They have a significant role in the management of cardiovascular disease.

Clinical Uses

They are used in the management of peripheral artery disease, as well as the prevention of coronary stent thrombosis and strokes.

Examples

Drugs in this class include: clopidogrel (Plavix),[2] prasugrel (Effient),[3] and ticlopidine (Ticlid).

Tinoridine was actually a predecessor to this work.

Alternatives

Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that is distinct from the mechanism of the thienopyridines in that it reversibly (rather than irreversibly) inhibits the P2Y12 receptor.[1]

References

  1. ^ a b Alexopoulos, Dimitrios (2014). "P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa". Cardiology. 127 (4): 211–219. doi:10.1159/000357399. PMID 24458006.
  2. ^ Depta, Jeremiah P.; Bhatt, Deepak L. (2008-01-01). "Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance". American Journal of Cardiovascular Drugs. 8 (2): 91–112. doi:10.1007/BF03256587. ISSN 1175-3277. PMID 18422393. S2CID 34689805.
  3. ^ Angiolillo DJ, Bates ER, Bass TA (August 2008). "Clinical profile of prasugrel, a novel thienopyridine". Am. Heart J. 156 (2 Suppl): S16–22. doi:10.1016/j.ahj.2008.06.005. PMID 18657682.


Categories